US FDA notes ‘disturbing lack of oversight’ over valsartan contamination 12-Dec-2018 By Ben Hargreaves Zhejiang Huahai received a warning letter from the US FDA, which observed that it ignored two separate customer complaints about contamination.
EMA places Zhejiang Huahai under ‘increased supervision’ over quality issues 17-Oct-2018 By Ben Hargreaves The EMA has placed Zhejiang Huahai under supervision, after the firm produced valsartan medication contaminated by probable carcinogens.